New drug shows promise for sinus fungal disease
NCT ID NCT04684524
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug dupilumab in 62 people with allergic fungal rhinosinusitis, a condition where fungus causes severe sinus inflammation. Participants received either dupilumab or a placebo injection for 52 weeks. The main goal was to see if dupilumab could reduce sinus blockage seen on CT scans and improve symptoms like nasal congestion and sense of smell.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (a biologic drug given as an injection under the skin)
What this could lead to
If it works, this could offer a new treatment option for people with allergic fungal rhinosinusitis, potentially reducing sinus blockage and the need for rescue treatments.
What could go wrong
This is a small Phase 3 trial with only 62 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC FUNGAL RHINOSINUSITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced ENT and Allergy Site Number : 8400004
Louisville, Kentucky, 40220, United States
-
Alamo ENT Associates Site Number : 8400018
San Antonio, Texas, 78258, United States
-
Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400001
Tampa, Florida, 33613, United States
-
Eastern Virginia Medical School (EVMS) Medical Group - Otola Site Number : 8400008
Norfolk, Virginia, 23507, United States
-
Emory University Hospital Midtown Campus Site Number : 8400009
Atlanta, Georgia, 30308, United States
-
Investigational Site Number : 0320001
CABA, Buenos Aires, C1425BEN, Argentina
-
Investigational Site Number : 0320002
Buenos Aires, C1121ABE, Argentina
-
Investigational Site Number : 0320003
CABA, Buenos Aires, C1414AIF, Argentina
-
Investigational Site Number : 0320004
Mendoza, 5500, Argentina
-
Investigational Site Number : 0320005
Rosario, Santa Fe Province, 2000, Argentina
-
Investigational Site Number : 1240001
Vancouver, British Columbia, V6Z 1Y6, Canada
-
Investigational Site Number : 1560001
Beijing, 100730, China
-
Investigational Site Number : 1560002
Nanjing, 210029, China
-
Investigational Site Number : 1560003
Chengdu, 610041, China
-
Investigational Site Number : 1560004
Changsha, 410013, China
-
Investigational Site Number : 1560005
Beijing, 100050, China
-
Investigational Site Number : 1560006
Hangzhou, 310003, China
-
Investigational Site Number : 1560008
Taiyuan, 030001, China
-
Investigational Site Number : 1560009
Shanghai, 200030, China
-
Investigational Site Number : 1560011
Qingdao, 266555, China
-
Investigational Site Number : 1560012
Hefei, China
-
Investigational Site Number : 1560013
Fuzhou, 350005, China
-
Investigational Site Number : 3560003
Coimbatore, 641028, India
-
Investigational Site Number : 3560006
Jodhpur, 342005, India
-
Investigational Site Number : 3560008
New Delhi, 110 062., India
-
Investigational Site Number : 3760001
Petah Tikva, 49100, Israel
-
Investigational Site Number : 3760002
Rehovot, 76100, Israel
-
Investigational Site Number : 3920001
Meguro-ku, Tokyo, 153-8515, Japan
-
Investigational Site Number : 3920003
Shinagawa-ku, Tokyo, 141-0001, Japan
-
Investigational Site Number : 3920006
Shizuoka, Shizuoka, 420-0853, Japan
-
Investigational Site Number : 3920008
Bunkyo-ku, Tokyo, 113-8431, Japan
-
Investigational Site Number : 3920009
Shinjuku-ku, Tokyo, 160-8582, Japan
-
Investigational Site Number : 3920010
Isehara, Kanagawa, 2591193, Japan
-
Investigational Site Number : 6820001
Riyadh, 22252, Saudi Arabia
-
Investigational Site Number : 6820002
Riyadh, 12713, Saudi Arabia
-
Investigational Site Number : 7920001
Istanbul, 34093, Turkey (Türkiye)
-
Investigational Site Number : 7920003
Izmir, 35340, Turkey (Türkiye)
-
Investigational Site Number : 7920004
Adana, 01380, Turkey (Türkiye)
-
Investigational Site Number : 7920005
Malatya, 44280, Turkey (Türkiye)
-
Investigational Site Number : 7920006
Izmir, 35100, Turkey (Türkiye)
-
Investigational Site Number : 7920007
Istanbul, 34865, Turkey (Türkiye)
-
National Allergy and Asthma Research, LLC Site Number : 8400002
Charleston, South Carolina, 29407, United States
-
REX Clinical Trials Site Number : 8400017
Beaumont, Texas, 77701-3713, United States
-
South Louisiana Ear, Nose, Throat and Facial Plastic Surgery Site Number : 8400019
Mandeville, Louisiana, 70471, United States
-
USA Clinical Trials Site Number : 8400020
San Antonio, Texas, 78229, United States
-
Ut- Houston Medical School Site Number : 8400010
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Center Site Number : 8400013
Nashville, Tennessee, 37232, United States